electroCore (ECOR) Q4 2024 earnings summary

Executive summary

• Achieved record 2024 revenue of $25.2 million, up 57% year-over-year, driven by strong VA/DoD and Truvaga sales, with Q4 revenue of $7 million marking the ninth consecutive record quarter.

• Net loss narrowed by 37% to $11.9 million for the year, with adjusted EBITDA net loss improving to $9 million from $15.4 million in 2023.

• Cash and equivalents at year-end were $12.2 million, with net cash used in operations reduced by 53% to $7 million.

• Significant growth in VA channel sales (up 85% to $17.8 million) and Truvaga wellness product sales (up 174% to $2.8 million).

• Announced acquisition of NeuroMetrix and distribution agreement with Spark Biomedical to expand product portfolio in chronic pain and opioid withdrawal.

Financial highlights

• Gross margin increased to 85% for 2024 from 83% in 2023, with gross profit at $21.4 million.

• Operating expenses rose to $33.6 million, mainly due to higher sales and marketing costs, while R&D expenses decreased to $2.4 million.

• Net loss per share improved to $1.59 from $3.42 year-over-year.

• Adjusted EBITDA net loss improved to $9 million from $15.4 million.

• Cash and equivalents at year-end: $12.2 million, up from $10.6 million in 2023.

Outlook and guidance

• Expect gross margins to remain in the mid-80s for 2025, with potential for slight decline if new product mix becomes material.

• Refraining from providing 2025 guidance pending NeuroMetrix acquisition close; anticipate further growth in core and new product lines.

• Plan to expand salesforce in the second half of 2025 to drive further growth.

• Management aims to expand presence in key sales channels and progress toward profitability in 2025.

• Plans to grow addressable market through partnerships and inorganic initiatives.